

Rolf A Brekken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8475823/publications.pdf>

Version: 2024-02-01

238
papers

19,557
citations

10956

71
h-index

13338

130
g-index

254
all docs

254
docs citations

254
times ranked

28166
citing authors

#	ARTICLE	IF	CITATIONS
1	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. <i>Nature Cell Biology</i> , 2000, 2, 737-744.	4.6	2,487
2	Hypoxia-Inducible Factor 1 α Induces Fibrosis and Insulin Resistance in White Adipose Tissue. <i>Molecular and Cellular Biology</i> , 2009, 29, 4467-4483.	1.1	720
3	Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. <i>Cell Death and Differentiation</i> , 2016, 23, 962-978.	5.0	506
4	SPARC, a matricellular protein: at the crossroads of cell-matrix communication. <i>Matrix Biology</i> , 2001, 19, 815-827.	1.5	491
5	Pancreatic cancer stroma: an update on therapeutic targeting strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 487-505.	8.2	458
6	Role of VEGF-A in Vascularization of Pancreatic Islets. <i>Current Biology</i> , 2003, 13, 1070-1074.	1.8	351
7	Dichotomous effects of VEGF-A on adipose tissue dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5874-5879.	3.3	337
8	Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. <i>Nature Medicine</i> , 2009, 15, 1023-1030.	15.2	328
9	Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. <i>Oncogene</i> , 2002, 21, 7011-7026.	2.6	305
10	SPARC, a matricellular protein: at the crossroads of cell-matrix. <i>Matrix Biology</i> , 2000, 19, 569-580.	1.5	304
11	27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth. <i>Cell Reports</i> , 2013, 5, 637-645.	2.9	289
12	Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature. <i>Clinical Cancer Research</i> , 2007, 13, 323-330.	3.2	256
13	Angiogenic Role of LYVE-1-Positive Macrophages in Adipose Tissue. <i>Circulation Research</i> , 2007, 100, e47-57.	2.0	253
14	A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. <i>Nature Communications</i> , 2013, 4, 2035.	5.8	252
15	A Peptoid α -Antibody Surrogate That Antagonizes VEGF Receptor 2 Activity. <i>Journal of the American Chemical Society</i> , 2008, 130, 5744-5752.	6.6	220
16	Non-nuclear estrogen receptor β signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 2319-2330.	3.9	217
17	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. <i>PLoS ONE</i> , 2009, 4, e7464.	1.1	205
18	Exploration of Nanoparticle-Mediated Photothermal Effect of TMB-H ₂ O ₂ Colorimetric System and Its Application in a Visual Quantitative Photothermal Immunoassay. <i>Analytical Chemistry</i> , 2018, 90, 5930-5937.	3.2	201

#	ARTICLE	IF	CITATIONS
19	Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice. <i>Gastroenterology</i> , 2014, 146, 1339-1350.e1.	0.6	196
20	TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic Transformation. <i>Molecular Cell</i> , 2011, 41, 458-470.	4.5	187
21	Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice. <i>Cancer Research</i> , 2008, 68, 4340-4346.	0.4	175
22	Macrophage-Derived SPARC Bridges Tumor Cell-Extracellular Matrix Interactions toward Metastasis. <i>Cancer Research</i> , 2008, 68, 9050-9059.	0.4	174
23	Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras-Directed Therapy. <i>Molecular Cancer Research</i> , 2005, 3, 413-423.	1.5	173
24	Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. <i>Journal of Clinical Investigation</i> , 2003, 111, 487-495.	3.9	170
25	Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. <i>Molecular Cancer</i> , 2019, 18, 68.	7.9	169
26	Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. <i>JCI Insight</i> , 2019, 4, .	2.3	169
27	Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer. <i>PLoS ONE</i> , 2009, 4, e7669.	1.1	168
28	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 1732-1740.	3.9	166
29	Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1761-1771.	1.9	165
30	A transistor-like pH nanoprobe for tumour detection and image-guided surgery. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	163
31	Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. <i>Cancer Cell</i> , 2022, 40, 656-673.e7.	7.7	155
32	Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer. <i>Cell</i> , 2013, 155, 552-566.	13.5	151
33	SPARC: a matricellular regulator of tumorigenesis. <i>Journal of Cell Communication and Signaling</i> , 2009, 3, 255-273.	1.8	147
34	Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. <i>Cancer Research</i> , 2003, 63, 5376-80.	0.4	146
35	The VEGF family in cancer and antibody-based strategies for their inhibition. <i>MAbs</i> , 2010, 2, 165-175.	2.6	144
36	Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis. <i>Molecular Cancer Research</i> , 2004, 2, 215-224.	1.5	134

#	ARTICLE	IF	CITATIONS
37	Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. <i>Journal of Cell Communication and Signaling</i> , 2009, 3, 337-347.	1.8	131
38	Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. <i>Cancer Research</i> , 2015, 75, 3699-3705.	0.4	127
39	Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 246-255.	0.4	127
40	Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. <i>Endocrine-Related Cancer</i> , 2006, 13, 905-919.	1.6	125
41	Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend <i>C. elegans</i> lifespan. <i>Nature Communications</i> , 2017, 8, 2270.	5.8	121
42	Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor- β receptor type I inhibitor. <i>Oncotarget</i> , 2018, 9, 6659-6677.	0.8	112
43	Age-Related Changes in Vascular Endothelial Growth Factor Dependency and Angiotensin-1-Induced Plasticity of Adult Blood Vessels. <i>Circulation Research</i> , 2004, 94, 984-992.	2.0	111
44	Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Receptor-2 (FLK-1, KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 545-555.	1.3	106
45	RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas. <i>Cancer Discovery</i> , 2013, 3, 444-457.	7.7	104
46	SPARC-like 1 Regulates the Terminal Phase of Radial Glia-Guided Migration in the Cerebral Cortex. <i>Neuron</i> , 2004, 41, 57-69.	3.8	103
47	Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies. <i>British Journal of Cancer</i> , 2017, 117, 545-552.	2.9	103
48	Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 57-72.	1.2	101
49	Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic Cancer. <i>Cancer Research</i> , 2010, 70, 2852-2861.	0.4	99
50	Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β -Lapachone for Pancreatic Cancer Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 275-285.	3.2	96
51	SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 915-925.	1.2	94
52	Enhanced Heme Function and Mitochondrial Respiration Promote the Progression of Lung Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e63402.	1.1	92
53	BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 992-1001.	1.9	90
54	Targeting vascular endothelium with avidin microbubbles. <i>Ultrasound in Medicine and Biology</i> , 2005, 31, 1279-1283.	0.7	89

#	ARTICLE	IF	CITATIONS
55	Matrix control of pancreatic cancer: New insights into fibronectin signaling. <i>Cancer Letters</i> , 2016, 381, 252-258.	3.2	89
56	Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. <i>International Journal of Cancer</i> , 2007, 121, 2181-2191.	2.3	88
57	Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2014, 74, 1032-1044.	0.4	88
58	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2473-2485.	1.9	86
59	Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. <i>Journal of Clinical Investigation</i> , 2006, 116, 422-429.	3.9	84
60	TGF- β 2 and α 2 β 6 Integrin Act in a Common Pathway to Suppress Pancreatic Cancer Progression. <i>Cancer Research</i> , 2012, 72, 4840-4845.	0.4	82
61	CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. <i>Cancer Letters</i> , 2015, 359, 335-343.	3.2	82
62	The regulatory function of SPARC in vascular biology. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 3165-3173.	2.4	81
63	Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. <i>JCI Insight</i> , 2018, 3, .	2.3	81
64	SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. <i>Nature Communications</i> , 2017, 8, 14098.	5.8	80
65	Phosphorylation of Akt and ERK1/2 Is Required for VEGF-A/VEGFR2-Induced Proliferation and Migration of Lymphatic Endothelium. <i>PLoS ONE</i> , 2011, 6, e28947.	1.1	79
66	A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. <i>Oncogene</i> , 2017, 36, 5122-5133.	2.6	79
67	LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. <i>Journal of Clinical Investigation</i> , 2015, 125, 4063-4076.	3.9	79
68	Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. <i>Journal of Clinical Investigation</i> , 2014, 124, 824-834.	3.9	78
69	Hypoxia Studies with Pimonidazole in vivo. <i>Bio-protocol</i> , 2014, 4, .	0.2	77
70	NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β -lapachone. <i>Cell Death and Disease</i> , 2015, 6, e1599-e1599.	2.7	76
71	Progesterin-Dependent Progression of Human Breast Tumor Xenografts: A Novel Model for Evaluating Antitumor Therapeutics. <i>Cancer Research</i> , 2007, 67, 9929-9936.	0.4	75
72	Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6993-7000.	3.2	74

#	ARTICLE	IF	CITATIONS
73	Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. <i>Journal of the American College of Surgeons</i> , 2005, 200, 371-377.	0.2	74
74	The angiogenic ?vascular endothelial growth factor/flk-1(KDR) receptor? pathway in patients with endometrial carcinoma. <i>Cancer</i> , 2001, 92, 2569-2577.	2.0	73
75	K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways. <i>Molecular Cancer Research</i> , 2009, 7, 799-808.	1.5	72
76	Semaphorin 3B Inhibits the Phosphatidylinositol 3-Kinase/Akt Pathway through Neuropilin-1 in Lung and Breast Cancer Cells. <i>Cancer Research</i> , 2008, 68, 8295-8303.	0.4	71
77	Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 2652.	1.7	71
78	Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. <i>International Journal of Cancer</i> , 2006, 118, 2639-2643.	2.3	70
79	Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGF β 2 Activation. <i>PLoS ONE</i> , 2012, 7, e31384.	1.1	69
80	Loss of SPARC in bladder cancer enhances carcinogenesis and progression. <i>Journal of Clinical Investigation</i> , 2013, 123, 751-66.	3.9	69
81	Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. <i>Molecular Cancer Research</i> , 2004, 2, 215-24.	1.5	68
82	SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H841-H847.	1.5	66
83	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020, 15, 973-999.	0.5	66
84	SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF β 1 activity. <i>Journal of Cell Biology</i> , 2011, 193, 1305-1319.	2.3	64
85	Recruitment and retention: factors that affect pericyte migration. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 299-309.	2.4	64
86	Compromised Production of Extracellular Matrix in Mice Lacking Secreted Protein, Acidic and Rich in Cysteine (SPARC) Leads to a Reduced Foreign Body Reaction to Implanted Biomaterials. <i>American Journal of Pathology</i> , 2003, 162, 627-635.	1.9	63
87	PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1190-1201.	1.9	63
88	Human pancreatic cancer cell exosomes, but not human normal cell exosomes, act as an initiator in cell transformation. <i>ELife</i> , 2019, 8, .	2.8	63
89	The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis. <i>Cancers</i> , 2021, 13, 6206.	1.7	63
90	Forced Expression of MMP9 Rescues the Loss of Angiogenesis and Abrogates Metastasis of Pancreatic Tumors Triggered by the Absence of Host SPARC. <i>Experimental Biology and Medicine</i> , 2008, 233, 860-873.	1.1	62

#	ARTICLE	IF	CITATIONS
91	SPARC Promotes Cathepsin B-Mediated Melanoma Invasiveness through a Collagen I/ $\alpha 2 \beta 1$ Integrin Axis. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2438-2447.	0.3	61
92	Vascular Endothelial Growth Factor Receptor-2 Promotes the Development of the Lymphatic Vasculature. <i>PLoS ONE</i> , 2013, 8, e74686.	1.1	61
93	SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. <i>Molecular Cancer</i> , 2014, 13, 237.	7.9	60
94	DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. <i>JCI Insight</i> , 2021, 6, .	2.3	60
95	Malignant Progression and Blockade of Angiogenesis in a Murine Transgenic Model of Neuroblastoma. <i>Cancer Research</i> , 2007, 67, 9435-9442.	0.4	58
96	The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. <i>BMC Cancer</i> , 2008, 8, 352.	1.1	58
97	P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. <i>Cell Reports</i> , 2016, 14, 2193-2208.	2.9	58
98	Role of SPARC in Bone Remodeling and Cancer-Related Bone Metastasis. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 17-26.	1.2	57
99	Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and $\beta 2$ AR-Dependent Neo-Angiogenic Switch. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1442-1454.	3.1	57
100	Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. <i>Wound Repair and Regeneration</i> , 2001, 9, 522-530.	1.5	56
101	Loss of fibulin-5 binding to $\beta 1$ integrins inhibits tumor growth by increasing the level of ROS. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 333-342.	1.2	56
102	Neutralizing Murine TGF $\beta 2$ Promotes a Differentiated Tumor Cell Phenotype and Inhibits Pancreatic Cancer Metastasis. <i>Cancer Research</i> , 2014, 74, 4996-5007.	0.4	56
103	Targeting α TGF $\beta 2$ mutant tumors exposes vulnerabilities to stromal α TGF $\beta 2$ blockade in pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10515.	3.3	56
104	Expression and Characterization of Murine Hevin (SC1), a Member of the SPARC Family of Matricellular Proteins. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 735-748.	1.3	55
105	SMAC Mimetic (JP1201) Sensitizes Non-Small Cell Lung Cancers to Multiple Chemotherapy Agents in an IAP-Dependent but TNF-Independent Manner. <i>Cancer Research</i> , 2011, 71, 7640-7648.	0.4	55
106	Vascular channels formed by subpopulations of PECAM1+ melanoma cells. <i>Nature Communications</i> , 2014, 5, 5200.	5.8	55
107	From top to bottom: midkine and pleiotrophin as emerging players in immune regulation. <i>Journal of Leukocyte Biology</i> , 2017, 102, 277-286.	1.5	55
108	The matricellular protein SPARC is expressed in human trabecular meshwork. <i>Experimental Eye Research</i> , 2003, 77, 601-607.	1.2	54

#	ARTICLE	IF	CITATIONS
109	Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5031-5042.	3.2	54
110	Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B. <i>Nature Chemical Biology</i> , 2015, 11, 401-408.	3.9	54
111	Strategies for vascular targeting in tumors. <i>International Journal of Cancer</i> , 2002, 100, 123-130.	2.3	53
112	Incorporation of Bone Marrow-derived Flk-1-expressing CD34+ Cells in the Endothelium of Tumor Vessels in the Mouse Brain. <i>Neurosurgery</i> , 2006, 59, 374-382.	0.6	53
113	Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5911-5916.	2.9	51
114	Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15999-16004.	3.3	50
115	Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. <i>Cell Death and Differentiation</i> , 2019, 26, 382-393.	5.0	49
116	Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 567-580.	1.2	48
117	MRI Detection of VEGFR2 <i>in Vivo</i> Using a Low Molecular Weight Peptoid [®] (Gd) ₈ -Dendron for Targeting. <i>Journal of the American Chemical Society</i> , 2010, 132, 12829-12831.	6.6	48
118	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. <i>Cancer Letters</i> , 2015, 358, 59-66.	3.2	48
119	Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. <i>BMC Cancer</i> , 2017, 17, 87.	1.1	48
120	Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25880-25890.	3.3	47
121	The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. <i>International Journal of Cancer</i> , 2007, 120, 753-760.	2.3	44
122	2-Amino-2,3-dihydro-1 <i>H</i> -indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and <i>In Vivo</i> Antipancreatic Cancer Efficacy. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7431-7444.	2.9	43
123	The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. <i>Science Translational Medicine</i> , 2016, 8, 365ra159.	5.8	42
124	Functional Analysis of the Matricellular Protein SPARC with Novel Monoclonal Antibodies. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 723-733.	1.3	40
125	Telomerase-Mediated Strategy for Overcoming Non-“Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. <i>Neoplasia</i> , 2018, 20, 826-837.	2.3	40
126	Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. <i>Experimental Biology and Medicine</i> , 2010, 235, 3-9.	1.1	39

#	ARTICLE	IF	CITATIONS
127	Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Immunology</i> , 2019, 202, 292-299.	0.4	39
128	Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. <i>Oncotarget</i> , 2014, 5, 9811-9822.	0.8	39
129	r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction. <i>PLoS ONE</i> , 2010, 5, e12031.	1.1	38
130	Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor. <i>Nature Cell Biology</i> , 2017, 19, 1226-1236.	4.6	38
131	Inhibition of Discoidin Domain Receptor 1 Prevents Stroma-Induced Peritoneal Metastasis in Gastric Carcinoma. <i>Molecular Cancer Research</i> , 2018, 16, 1590-1600.	1.5	38
132	The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer. <i>Cancer Research</i> , 2019, 79, 328-330.	0.4	38
133	Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. <i>Experimental Biology and Medicine</i> , 2010, 235, 263-270.	1.1	37
134	Lack of immunological fitness during fasting in metabolically challenged animals. <i>Journal of Lipid Research</i> , 2012, 53, 1254-1267.	2.0	37
135	GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. <i>BMC Cancer</i> , 2010, 10, 397.	1.1	36
136	Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1. <i>Oncotarget</i> , 2016, 7, 30678-30690.	0.8	36
137	Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulinitis and Restoring Islet Function. <i>Diabetes</i> , 2013, 62, 2870-2878.	0.3	35
138	Hypoxia and Transforming Growth Factor β^2 Cooperate to Induce Fibulin-5 Expression in Pancreatic Cancer. <i>Journal of Biological Chemistry</i> , 2016, 291, 22244-22252.	1.6	35
139	<i>MYC</i> Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 542-561.	7.7	35
140	Stromal Platelet-Derived Growth Factor Receptor β (PDGFR β) Provides a Therapeutic Target Independent of Tumor Cell PDGFR β Expression in Lung Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2473-2482.	1.9	34
141	VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. <i>Molecular Therapy</i> , 2013, 21, 1014-1023.	3.7	34
142	Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 1-14.	2.7	34
143	The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5892-5894.	1.0	33
144	Accumulation of Pro-Cancer Cytokines in the Plasma Fraction of Stored Packed Red Cells. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 460-468.	0.9	33

#	ARTICLE	IF	CITATIONS
145	Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 5058-5069.	0.4	33
146	Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1357-1362.	0.5	32
147	Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 327-332.	1.3	31
148	Assessment of TANK-binding kinase 1 as a therapeutic target in cancer. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 83-90.	1.8	31
149	Getting a grip on adhesion: Cadherin switching and collagen signaling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 118472.	1.9	31
150	Expression of Soluble VEGF Receptor 2 and Characterization of Its Binding by Surface Plasmon Resonance. <i>Biochemical and Biophysical Research Communications</i> , 1998, 252, 643-648.	1.0	29
151	SPARC-thrombospondin-2-double-null Mice Exhibit Enhanced Cutaneous Wound Healing and Increased Fibrovascular Invasion of Subcutaneous Polyvinyl Alcohol Sponges. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 571-581.	1.3	29
152	Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. <i>Cancer Biology and Therapy</i> , 2011, 12, 617-628.	1.5	29
153	SPARC is a key mediator of TGF β -induced renal cancer metastasis. <i>Journal of Cellular Physiology</i> , 2021, 236, 1926-1938.	2.0	29
154	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	3.3	29
155	Selective Blockade of Vascular Endothelial Growth Factor Receptor 2 With an Antibody Against Tumor-Derived Vascular Endothelial Growth Factor Controls the Growth of Human Pancreatic Adenocarcinoma Xenografts. <i>Annals of Surgical Oncology</i> , 2006, 13, 1145-1155.	0.7	28
156	Inhibition of Multiple Pathogenic Pathways by Histone Deacetylase Inhibitor SAHA in a Corneal Alkali-Burn Injury Model. <i>Molecular Pharmaceutics</i> , 2013, 10, 307-318.	2.3	28
157	Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells. <i>ACS Chemical Biology</i> , 2015, 10, 2891-2899.	1.6	28
158	Direct and indirect regulation of the tumor immune microenvironment by VEGF. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1269-1286.	1.5	28
159	A peptoid antagonist of VEGF Receptor 2 recognizes a "hotspot"™ in the extracellular domain distinct from the hormone-binding site. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 6338-6343.	1.4	26
160	Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	26
161	Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. <i>PLoS ONE</i> , 2016, 11, e0158757.	1.1	25
162	Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. <i>Gastric Cancer</i> , 2020, 23, 824-836.	2.7	25

#	ARTICLE	IF	CITATIONS
163	The Acellular Fraction of Stored Platelets Promotes Tumor Cell Invasion. <i>Journal of Surgical Research</i> , 2009, 153, 132-137.	0.8	24
164	Clonal Analysis Reveals a Common Progenitor for Endothelial, Myeloid, and Lymphoid Precursors in Umbilical Cord Blood. <i>Circulation Research</i> , 2010, 107, 1460-1469.	2.0	24
165	Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3170-3180.	0.4	24
166	Epithelialâ€mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. <i>Carcinogenesis</i> , 2012, 33, 1639-1646.	1.3	24
167	Extracellular Matrix Induction of Intracellular Reactive Oxygen Species. <i>Antioxidants and Redox Signaling</i> , 2017, 27, 774-784.	2.5	24
168	Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- <i>a</i>]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7977-7990.	2.9	24
169	Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 1049.	1.3	24
170	Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer. <i>American Journal of Physiology - Cell Physiology</i> , 2020, 319, C233-C243.	2.1	23
171	TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy. <i>Cell Communication and Signaling</i> , 2020, 18, 29.	2.7	23
172	Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice. <i>Cancer</i> , 2010, 116, 3862-3874.	2.0	22
173	VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. <i>JCI Insight</i> , 2021, 6, .	2.3	22
174	Does Axl have potential as a therapeutic target in pancreatic cancer?. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 955-966.	1.5	21
175	VEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer. <i>Cancers</i> , 2010, 2, 970-988.	1.7	20
176	Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 531-540.	1.6	20
177	Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction. <i>Molecular Metabolism</i> , 2018, 16, 139-149.	3.0	20
178	AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. <i>IScience</i> , 2020, 23, 101649.	1.9	20
179	Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2020, 13, 911-922.	0.7	20
180	Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. <i>Annals of Surgical Oncology</i> , 2016, 23, 583-591.	0.7	18

#	ARTICLE	IF	CITATIONS
181	Perspectives on Hypoxia Signaling in Tumor Stroma. <i>Cancers</i> , 2021, 13, 3070.	1.7	18
182	Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 662-670.	1.9	17
183	Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. <i>Oncotarget</i> , 2016, 7, 51569-51580.	0.8	17
184	Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 180.e1-180.e7.	0.7	16
185	Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6017-6027.	3.2	16
186	AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1412-1421.	1.5	16
187	Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , 2003, 90, 492-501.	1.2	14
188	A rapid <i>in vivo</i> screen for pancreatic ductal adenocarcinoma therapeutics. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1201-1211.	1.2	14
189	Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 348-355.	1.5	14
190	CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target. <i>Cancers</i> , 2022, 14, 86.	1.7	14
191	β -Np63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leader-Follower Relationship That Drives Collective Invasion. <i>Cancer Research</i> , 2020, 80, 3933-3944.	0.4	13
192	Hemolysis-associated phosphatidylserine exposure promotes polyclonal plasmablast differentiation. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	12
193	Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 493-503.	1.0	12
194	The effect of flow on blood oxygen level dependent (R_2^*) MRI of orthotopic lung tumors. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 3787-3797.	1.9	11
195	Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo. , 2015, 56, 7137.		10
196	Neuropathological Effects of Chemotherapeutic Drugs. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3038-3048.	1.7	10
197	AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 38-47.	1.9	9
198	Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 313-319.	1.7	8

#	ARTICLE	IF	CITATIONS
199	The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy. <i>Current Drug Targets</i> , 2016, 17, 1747-1754.	1.0	8
200	Effective Rat Lung Tumor Model for Stereotactic Body Radiation Therapy. <i>Radiation Research</i> , 2016, 185, 616-622.	0.7	7
201	<p>APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice<p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 249-259.	1.0	7
202	High-dimensional immunotyping of tumors grown in obese and non-obese mice. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	7
203	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 3183-3183.	3.9	7
204	Î²1 Syntrophin Supports Autophagy Initiation and Protects against Cerulein-Induced Acute Pancreatitis. <i>American Journal of Pathology</i> , 2019, 189, 813-825.	1.9	6
205	Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis. <i>Cancer Discovery</i> , 2014, 4, 25-26.	7.7	5
206	Stromal TGFÎ²R2 signaling: a gateway to progression for pancreatic cancer. <i>Molecular and Cellular Oncology</i> , 2015, 2, e975606.	0.3	5
207	Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. <i>Archives of Biochemistry and Biophysics</i> , 2019, 661, 97-106.	1.4	5
208	Loss of BAP1 Leads to More YAPing in Pancreatic Cancer. <i>Cancer Research</i> , 2020, 80, 1624-1625.	0.4	5
209	Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. <i>Anticancer Research</i> , 2011, 31, 843-7.	0.5	5
210	Targeting TAM to Tame Pancreatic Cancer. <i>Targeted Oncology</i> , 2020, 15, 579-588.	1.7	4
211	Anti-VEGF Therapy Revived by c-Met Inhibition, but Is c-Met the Answer?. <i>Cancer Discovery</i> , 2012, 2, 211-213.	7.7	3
212	Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. <i>Scientific Reports</i> , 2020, 10, 20662.	1.6	3
213	Mesothelial Cell-Derived Antigen-Presenting Cancer-Associated Fibroblasts Induce Expansion of Regulatory T Cells in Pancreatic Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
214	Beyond Stiffness. <i>American Journal of Pathology</i> , 2020, 190, 1622-1624.	1.9	3
215	Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models.. <i>Clinical Cancer Research</i> , 2014, 20, B30-B30.	3.2	3
216	Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9081-9081.	0.8	3

#	ARTICLE	IF	CITATIONS
217	Collagen Signaling in Cancer. , 2019, , 89-108.		2
218	Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. Blood, 2021, 137, 1839-1842.	0.6	2
219	Targeting Inside-Out Phospholipids on Tumor Blood Vessels in Pancreatic Cancer. , 2006, , 179-194.		1
220	147. The Acellular Fraction of Stored Platelets Promotes Cancer Invasion. Journal of Surgical Research, 2008, 144, 241-242.	0.8	1
221	Update on vascular disrupting agents for cancer therapy. Therapy: Open Access in Clinical Medicine, 2011, 8, 403-413.	0.2	1
222	Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-stimulated T Cell IFN- γ and TNF- α Production. Journal of Immunology, 2021, 207, 436-448.	0.4	1
223	Drivers of EMT and Immune Evasion. , 2017, , 221-239.		1
224	Mouse Models of Pancreatic Cancer. , 2013, , 57-91.		1
225	Abstract A04: TBK1 as a novel mediator of K-Ras driven pancreatic cancer. , 2014, , .		1
226	Are TEMs Canceled? Questioning the Functional Relevance of Tie2-Expressing Macrophages. Cancer Research, 2022, 82, 1172-1173.	0.4	1
227	The Extracellular Matrix of Tumors: A Focus on Fibronectin and Fibulin-5. Biology of Extracellular Matrix, 2017, , 1-15.	0.3	0
228	Location matters: Profiling diffuse type gastric cancer at the single cell level. Clinical Cancer Research, 2021, 27, clincanres.2935.2021.	3.2	0
229	The Function of SPARC in Tumor Cell Biology: SPARC as a Modulator of Cell-Extracellular Matrix Interaction. , 2010, , 171-189.		0
230	SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF- β 1 activity. Journal of Experimental Medicine, 2011, 208, i22-i22.	4.2	0
231	Effect of 2G8, a TGF- β 2 inhibitor, on TGF- β signaling and migration in an immunocompetent pancreatic cancer model. Journal of Clinical Oncology, 2012, 30, 230-230.	0.8	0
232	Use of PG545, a heparanase inhibitor, to inhibit pancreatic cancer tumor cell proliferation and migration in vitro and in vivo. Journal of Clinical Oncology, 2012, 30, 234-234.	0.8	0
233	Rgs16 is a pancreatic reporter of chronic hyperglycemia in diabetes. FASEB Journal, 2012, 26, 759.6.	0.2	0
234	Ligand induced activation of VEGFR during angiogenesis. FASEB Journal, 2012, 26, 971.2.	0.2	0

#	ARTICLE	IF	CITATIONS
235	Stromal and antitumor effects of BIBF 1120 (nintedanib) in a preclinical lung cancer model.. Journal of Clinical Oncology, 2012, 30, e13563-e13563.	0.8	0
236	Abstract B19: Rapid in vivo screen of pancreatic ductal adenocarcinoma therapeutics. , 2014, , .		0
237	919â€¦Tegavivint reduces the immunosuppressive macrophage phenotype in a preclinical co-culture model of the non-small cell lung cancer tumor microenvironment. , 2021, 9, A964-A964.		0
238	Procoagulant Activity of Skeletal Muscle Myosin Is Not Caused By Contaminating Phosphatidylserine-Vesicles. Blood, 2020, 136, 20-21.	0.6	0